BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is engaged in the development of small molecule drugs that are designed to block key enzymes involved in inflammatory and infectious diseases. The company’s FDA-approved Rapivab® is a treatment for acute uncomplicated influenza. The company’s pipeline includes treatment candidates for hereditary angioedema (HAE) and a broad spectrum antiviral for hemorrhagic fevers.